© Copyright Our Wall
The global mRNA therapeutics and mRNA vaccine market is
witnessing steady growth, estimated to be worth USD 51.3 billion in 2023.
In recent years, the mRNA vaccine and
therapeutics markethas grown significantly,
driven by increasing demand for targeted therapies to treat diseases that are
difficult to address with conventional drugs. Messenger RNA (mRNA), a
single-stranded ribonucleic acid that encodes proteins, has emerged as a
revolutionary drug class for managing infectious, chronic, and oncological
disorders. Pharmaceutical companies have recognized the potential of mRNA-based
therapies, particularly for treating conditions such as COVID-19, genetic
disorders, cancer, and other infectious diseases.
Despite its promise, the market faces challenges. Stringent
regulatory guidelines and the availability of pre-existing vaccines based on
other technologies have contributed to a decline in market momentum.
Additionally, as the COVID-19 pandemic transitions into an endemic phase, the
demand for mRNA vaccines is expected to decrease, contributing to a potential
downturn in the market during the forecast period.
Competitive
Landscape of the mRNA Therapeutics and Vaccine Market
Currently, the mRNA therapeutics
and vaccine market landscape features more than 35 companies engaged in
evaluating over 195 mRNA therapeutics and mRNA vaccines across different
clinical and development stages. In the coming years, several pharmaceutical
companies such as Moderna, Merck, Sanofi, and Daiichi Sankyo will enroll in
strategic partnerships with mRNA-based therapeutics and vaccine developers to
expand their therapy development capabilities.
Key
Report Takeaway
⬝
The pipeline features
several drugs, which are being investigated across different phases of
development; over 75% of the pipeline candidates are designed for delivery via
the intramuscular and intravenous routes.
⬝
The market's evolution
is likely to be driven by the rising need for novel drug candidates; we expect
the future opportunity to be well-distributed across various routes of
administration, therapeutic areas, and key regions.
⬝
Several investors, having
realized the opportunity within this upcoming segment, have invested over USD
11 billion across various funding rounds in the past nine years.
⬝
More than 345,000
patients have been recruited / enrolled in clinical trials registered for this
novel class of therapies across different geographies.
⬝
Stakeholders are
actively upgrading their existing capabilities to further enhance their
respective product pipelines and comply with the evolving industry benchmarks.
⬝
The growing interest
is evident from the rise in partnership activity since 2021; clinical trial
agreements have emerged as the most common type of partnership model adopted by
drug developers.
⬝
With over 195
candidates under development, mRNA therapeutics, and vaccines currently
represent one of the fastest-growing drug classes in the pharmaceutical market.
⬝
Big pharma players
have undertaken several initiatives, from proprietary product development to
strategic investments, to tap the lucrative opportunity in this rapidly growing
market.
mRNA
Therapeutics and Vaccine Market Segments
Based on the research report, Roots Analysis has segmented
the mRNA Therapeutics and Vaccine market into the types of secondary packaging,
primary packaging, and key geographical regions.
⬝ mRNA
Therapeutics and Vaccine Market, Based on Expertise
⬝ mRNA
Therapeutics
⬝ mRNA
Vaccines
⬝ mRNA
Therapeutics and Vaccine Market, Based on Route of Administration
⬝ Intravenous
⬝ Intramuscular
⬝ Intranasal
⬝ Others
⬝ mRNA
Therapeutics and Vaccine Market, Based on Key Geographical Regions
⬝ North
America
⬝ Europe
⬝ Asia-Pacific
⬝ Middle
East and North Africa
⬝ Latin
America
⬝ Rest
of the World
mRNA
Therapeutics and Vaccine Market Geographical Outlook
The mRNA therapeutics and vaccine
market based on geographical region is segmented into North America, Europe,
Asia-Pacific, Latin America, the Middle East, North Africa, and the rest of the
world. North America is dominating the mRNA therapeutic and vaccine market,
holding the largest share of overall revenue. The National Institutes of Health
supports research and development of mRNA therapeutics through grants even
before the pandemic. Active support from regulatory authorities and government
initiatives is driving the market in North America during the forecast period.
mRNA
Therapeutics and Vaccine Market Key Players
Examples of the key companies engaged in the mRNA
Therapeutics and Vaccine market (which have also been profiled in the market
report; the complete list of the companies is also included in the full report)
include:
▪
IMMORNA
▪
BioNTec
▪
eTheRNA
▪
Stemirna Therapeutics.
▪
Moderna
▪
Omega Therapeutics
▪
Chimeron Bio
▪
CureVac
▪
RNACure
It is worth noting the ongoing
developments and collaborations in the mRNA therapeutics and vaccine market,
which anticipate steady growth. An example of such a partnership includes:
⬝
In August, Moderma and CARsgen Therapeutics entered
into a collaboration to combine their respective mRNA therapeutics cancer
vaccine with a solid tumor CAR-T cell therapy for the treatment of individuals
with multiple cancers.
⬝
In June 2023, Providence Therapeutics collaborated with
the University Health Network (UHN) to develop mRNA-based therapeutics and
vaccines to treat patients with cancer and infectious diseases.
In April 2023, Moderna and IBM collaborated to explore advanced next
generation technologies such as artificial intelligence and quantum computing
in order to enhance their mRNA research and science.
To get market data, market insights,
financial statements, and a comprehensive analysis of themRNA Therapeutics and mRNA Vaccine market, please contact [email protected]
You Can Order the Complete Report on the MRNA
Therapeutics and Vaccine Market Online by Clicking On the Given Link
https://www.rootsanalysis.com/reports/mrna-therapeutics-and-vaccines-market.html
About Roots Analysis
Roots
Analysisis a global leader in the pharma
/ biotech market research. Having worked with over 750 clients worldwide,
including Fortune 500 companies, start-ups, academia, venture capitalists, and
strategic investors for over a decade, we offer a highly analytical /
data-driven perspective to a network of over 450,000 senior industry
stakeholders looking for credible market insights. All reports provided by us
are structured in a way that enables the reader to develop a thorough
perspective on the given subject. Apart from writing reports on identified
areas, we provide bespoke research /
consulting servicesdedicated to serving
our clients in the best possible way.
Contact
US
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: [email protected]or [email protected]
Website: https://www.rootsanalysis.com
The Wall